mCRPC Patient Case Study: A Nuclear Medicine perspective

These case studies were developed as a promotional educational resource and share real-world experience from experts on the treatment and management of their patients with metastatic castration-resistant prostate cancer (mCRPC). Each case study covers the whole patient journey, from initial diagnosis and treatment decisions to outcomes and tolerability.

These case studies share a range of different patient profiles including different ages, treatment histories, concomitant medications and outcomes to help visualise and identify eligible mCRPC patients who may be suitable for treatment with Xofigo.

mCRPC Patient Case Study: A Nuclear Medicine perspective

By Dr Francis Sundram, Consultant Clinical Lead, Department of Nuclear Medicine, University Hospital Southampton NHS Foundation Trust, Southampton.

Patient: 62 years old when diagnosed with advanced prostate cancer who was chemo-ineligible due to his cardiac history.

Treatment goal: Prolong survival, reduce or improve the symptoms of bone-metastases, slow down the decline of quality of life during on-treatment period and to prolong time to skeletal-related events vs placebo. 2^nd line treatment with Xofigo.

Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.

Xofigo▼ Prescribing Information

This patient case study is initiated and funded by Bayer plc. No patient identifiable data or photos of patients are shared within these case studies and the appropriate consent from the patients was collected by the HCP prior to development. Individual responses and experiences to medicinal products may vary.